Thermo Fisher Scientific Debuts Innovation?s in Bioprocess?ing at INTERPHEX 2014
Thermo Fisher Scientific Inc., the world leader in serving science, has introduced new innovations in cell culture and bioprocessing technologies to address the evolving requirements of biologic drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers. These advancements, including a new high-volume centrifugation system and controller platforms for its next-generation single-use bioreactor, will be showcased this week at INTERPHEX, Jacob Javitz Convention Center, New York City, 18–20 March 2014, Booth #3544.
“Thermo Fisher has combined exceptional technologies with a deep understanding of the challenges of bringing biologic pharmaceuticals from discovery to development and production,” said Cory Stevenson, president of the bioprocessing business at Thermo Fisher. “The combination of Thermo Scientific single-use technologies with the cell culture, purification, and analytics capabilities under the Life Technologies brand increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions. Doing so enhances their efficiency and productivity across the entire bioproduction workflow.”
Highlights at INTERPHEX include
• New Thermo Scientific bioreactor controller platforms for the Thermo Scientific single-use systems offer the choice, performance and flexibility. Developed with technology integration partners Applikon and Finesse and under the Thermo Scientific brand, the controllers meet the needs of both highly configurable cGMP and cost-effective research applications.
• New Thermo Scientific Sorvall RC BIOS 10 large-capacity centrifuge offers a new 10-L capacity for batch bioprocessing centrifugation. The system combines the centrifuge with carbon fiber rotors and paperless data collection software, to improve productivity and protects sample safety and integrity.
• Life Technologies products that span the biologics workflow and include a portfolio of premium solutions and services focused on upstream cell culture, downstream purification and analytics for detection and quantitation of process/product impurities and contaminants. Products on display include Life Technologies Gibco cell culture media and feeds in both liquid and AGT Dry Media formats, GoPure Prepacked and POROS A, G and CaptureSelect Chromatography Columns, and MycoSEQ Myccoplasma Detection System.
• The industry-leading Thermo Scientific Aegis5-14 Film, the most advanced film for demanding cell culture and single-use bioprocessing applications.
• The Thermo Scientific HyPerforma Single-Use Bioreactor (SUB), which offers all of the advantages of previous SUBs while offering advancements that make it easier to manage tubing systems and loading of single-use Thermo Scientific bioprocess containers. The SUBs also feature faster heat up and cool down, flexible positioning, and height-adjustable single- or dual-filter brackets.
The combination of Thermo Scientific’s single-use and bioprocessing technologies with the cell culture, purification, and analytics business from Life Technologies increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions across the entire bioproduction workflow.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance